Scotland approves new treatment option for multiple myeloma patients
I'm PortAI, I can summarize articles.
Scotland's Scottish Medicines Consortium has approved GSK's Blenrep (belantamab mafodotin) in combination with bortezomib and dexamethasone as a second-line treatment for relapsed or refractory multiple myeloma patients. This decision, based on the DREAMM-7 study, is expected to benefit around 300 patients annually, showing significant improvements in progression-free survival and a 42% reduction in death risk. Healthcare professionals express optimism about the therapy's potential to enhance patient quality of life.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: PharmaTimes The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments